Oscar Health (OSCR) is no longer just a flashy disruptor—it’s aiming for profitability. With CEO Mark Bertolini buying $11.9M in stock and revenue projected to hit $19B in 2026, this could be one of the most compelling turnaround plays in healthcare.

Read entire article

Phreesia just hit profitability—and got punished for it. With insiders loading up and institutions fully committed, is this a classic overreaction or a value trap? Let’s decode the dip.

Read entire article

Lululemon (LULU) has fallen sharply from its highs, but insider buying and international growth suggest opportunity. Is this a contrarian buy—or a value trap in disguise?

Read entire article

Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.

Read entire article

Sprouts Farmers Market stock has fallen sharply from its 2025 highs, yet the company continues to grow sales, generate strong profits, and buy back shares. With insider buying and heavy institutional ownership, the setup is intriguing.

Read entire article

SoFi just delivered its first billion-dollar quarter, record member growth, and a fresh insider buy from CEO Anthony Noto. The fintech story is evolving from speculative startup to profitable platform — but valuation and skepticism remain. Here’s the FUNanc1al breakdown of the opportunity.

Read entire article

After a sharp decline, CoStar Group (CSGP) insiders are stepping in to buy shares. With dominant commercial real estate data, rapid Homes.com growth, and strong institutional backing, investors are asking whether the market is underestimating the company’s long-term potential.

Read entire article

The Trade Desk just got the loudest kind of bullish signal: the founder-CEO bought $148M of his own stock after an 80%+ drawdown. Institutions are stacked, shorts are circling, and valuation has finally cooled from “bubble” to “business.” The question now: is TTD a generational dip… or a beautiful trap?

Read entire article

Insulet (PODD) just delivered 31% revenue growth and insiders are buying — yet the stock trades at 70x earnings. Is this premium medtech compounder a long-term winner or priced for perfection? Here’s the FUNanc1al breakdown.

Read entire article

DraftKings isn’t just a sportsbook anymore—it’s becoming an “internet casino layer” built on attention, probability, and habit loops. With a major insider purchase, heavy institutional ownership, improving margins, and the stock still far below its highs, DKNG may be entering its most interesting chapter yet.

Read entire article